search
Back to results

Evaluation of Diphenhydramine Hydrochloride Effects in Subjects With Occasional Sleeplessness

Primary Purpose

Occasional Sleeplessness

Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Diphenhydramine Hydrochloride
Placebo
Sponsored by
Procter and Gamble
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Occasional Sleeplessness

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • be male or female subjects, ≥18 years of age to 55 years of age, who report that they are currently experiencing occasional sleeplessness characterized by difficulty initiating sleep (ie, taking ≥30 minutes to fall asleep) on average 2-4 times per week for less than 1 month;
  • be in good general health without clinically significant disease (no previously diagnosed sleep disorders);
  • if female, have a negative screening pregnancy test and agree to be on approved methods of birth control throughout the study

Exclusion Criteria:

  • have a clinically significant illness within 30 days of Screening;
  • are taking medication that could interfere with the study medication;
  • have been under a clinician's care for insomnia treatment and control within the past year or has a history of insomnia or is currently taking prescription medications for insomnia;
  • are currently taking medications known to effect sleep function;
  • have current or past history of serious, severe or unstable physical or psychiatric illness;
  • have current diagnosis of severe urinary retention;
  • have current diagnosis of untreated narrow angle glaucoma;
  • had participated in a clinical drug study or used an investigational new drug during the previous 30 days;
  • have any clinically significant or abnormal finding in physical examination, vital signs, ECG, or clinical laboratory tests that may affect the subject's safety or outcome of the study;

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Placebo Comparator

    Arm Label

    Diphenhydramine Hydrochloride

    Placebo

    Arm Description

    Diphenhydramine (50 mg) elixir taken when subjects had trouble falling asleep

    Placebo elixir taken when subjects had trouble falling asleep

    Outcomes

    Primary Outcome Measures

    Mean Latency to Persistent Sleep
    Per Protocol population based on subjects who completed treatment crossover

    Secondary Outcome Measures

    Full Information

    First Posted
    October 14, 2015
    Last Updated
    January 25, 2017
    Sponsor
    Procter and Gamble
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02578186
    Brief Title
    Evaluation of Diphenhydramine Hydrochloride Effects in Subjects With Occasional Sleeplessness
    Official Title
    Randomized, Double-Blind, Placebo-Controlled, Crossover, In-home Study to Assess the Efficacy of Diphenhydramine Hydrochloride in Subjects With Occasional Sleeplessness
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    January 2017
    Overall Recruitment Status
    Completed
    Study Start Date
    November 2013 (undefined)
    Primary Completion Date
    December 2014 (Actual)
    Study Completion Date
    December 2014 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Procter and Gamble

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The present study was conducted to investigate the impact of diphenhydramine hydrochloride on the ability to initiate sleep.
    Detailed Description
    Diphenhydramine hydrochloride (herein referred to as diphenhydramine) is an antihistamine of the ethanolamine classes with known sleep-inducing properties and is approved by the Food & Drug Administration to reduce the time to sleep onset in individuals having difficulty falling asleep. The goal of the study is to investigate diphenhydramine versus placebo with regard to several sleep parameters, including time to sleep onset, in healthy adult subjects suffering from occasional sleeplessness.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Occasional Sleeplessness

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 4
    Interventional Study Model
    Crossover Assignment
    Masking
    ParticipantCare ProviderInvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    33 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Diphenhydramine Hydrochloride
    Arm Type
    Experimental
    Arm Description
    Diphenhydramine (50 mg) elixir taken when subjects had trouble falling asleep
    Arm Title
    Placebo
    Arm Type
    Placebo Comparator
    Arm Description
    Placebo elixir taken when subjects had trouble falling asleep
    Intervention Type
    Drug
    Intervention Name(s)
    Diphenhydramine Hydrochloride
    Other Intervention Name(s)
    Zzzquil
    Intervention Description
    30 mL at bedtime
    Intervention Type
    Drug
    Intervention Name(s)
    Placebo
    Other Intervention Name(s)
    placebo comparator
    Intervention Description
    30 mL at bedtime
    Primary Outcome Measure Information:
    Title
    Mean Latency to Persistent Sleep
    Description
    Per Protocol population based on subjects who completed treatment crossover
    Time Frame
    4 weeks

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    55 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: be male or female subjects, ≥18 years of age to 55 years of age, who report that they are currently experiencing occasional sleeplessness characterized by difficulty initiating sleep (ie, taking ≥30 minutes to fall asleep) on average 2-4 times per week for less than 1 month; be in good general health without clinically significant disease (no previously diagnosed sleep disorders); if female, have a negative screening pregnancy test and agree to be on approved methods of birth control throughout the study Exclusion Criteria: have a clinically significant illness within 30 days of Screening; are taking medication that could interfere with the study medication; have been under a clinician's care for insomnia treatment and control within the past year or has a history of insomnia or is currently taking prescription medications for insomnia; are currently taking medications known to effect sleep function; have current or past history of serious, severe or unstable physical or psychiatric illness; have current diagnosis of severe urinary retention; have current diagnosis of untreated narrow angle glaucoma; had participated in a clinical drug study or used an investigational new drug during the previous 30 days; have any clinically significant or abnormal finding in physical examination, vital signs, ECG, or clinical laboratory tests that may affect the subject's safety or outcome of the study;

    12. IPD Sharing Statement

    Learn more about this trial

    Evaluation of Diphenhydramine Hydrochloride Effects in Subjects With Occasional Sleeplessness

    We'll reach out to this number within 24 hrs